Regulation S-K

INUVO ANNOUNCES ADDITIONAL SALES TO CLOSE OUT REGISTERED DIRECT OFFERING

Wednesday, April 1, 2020 - 9:15pm

The additional shares were offered and are expected to be sold to certain investors in a registered direct offering conducted without an underwriter or placement agent.

Key Points: 
  • The additional shares were offered and are expected to be sold to certain investors in a registered direct offering conducted without an underwriter or placement agent.
  • The expected net proceeds from the final closing of this offering, after deducting estimated offering expenses, will be approximately $245,050.
  • These final sales in the offering are expected to close on or around April 2, 2020.
  • This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Inuvo in the registered direct offering.

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Wednesday, April 1, 2020 - 3:06pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

One World Pharma Continues Colombian Operations Through Pandemic as Agriculture Declared an Essential Business

Wednesday, April 1, 2020 - 2:00pm

This press release contains "forward-looking statements" that include information relating to future events.

Key Points: 
  • This press release contains "forward-looking statements" that include information relating to future events.
  • Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved.
  • For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company's Current Report on 8-K/A filed with the Securities and Exchange Commission on July 12, 2019, which is available at www.sec.gov .
  • The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Tuesday, March 31, 2020 - 3:07pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results

Monday, March 30, 2020 - 9:05pm

Certain statements in this news release contain forward-looking statements within the meaning of the U.S.

Key Points: 
  • Certain statements in this news release contain forward-looking statements within the meaning of the U.S.
  • Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation statements containing the words "believe", "may", looking ahead, hope, "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions.
  • These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the years ended DECEMBER 31 2019, 2018 and 2017 (copies of which may be obtained at www.sedar.com or www.sec.gov ).
  • The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.

INUVO ANNOUNCES $545,000 REGISTERED DIRECT OFFERING

Friday, March 27, 2020 - 8:15pm

Inuvo raised approximately $535,125 in this offering after deducting estimated expenses incurred in connection with the offering.

Key Points: 
  • Inuvo raised approximately $535,125 in this offering after deducting estimated expenses incurred in connection with the offering.
  • Inuvo plans to use the net proceeds from the offering for working capital.
  • This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Inuvo in the offering or otherwise.
  • Inuvo further expressly disclaims any written or oral statements made by a third party regarding the subject matter of this press release.

One World Pharma Uses Colombian THC Quota for 2020 and Begins Cultivation of 13 Different Strains in Next Step of Characterization Process

Thursday, March 26, 2020 - 1:00pm

This press release contains "forward-looking statements" that include information relating to future events.

Key Points: 
  • This press release contains "forward-looking statements" that include information relating to future events.
  • Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved.
  • For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company's Current Report on 8-K/A filed with the Securities and Exchange Commission on July 12, 2019, which is available at www.sec.gov .
  • The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

GAN Announces Public Filing of Registration Statement on Form F-1 for U.S. Listing on the Nasdaq; Provides 2019 Financial Overview / Trading and COVID-19 Update

Wednesday, March 25, 2020 - 11:00am

The Company is publicly filing a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the SEC) today relating to the proposed public listing of common stock in GAN Limited.

Key Points: 
  • The Company is publicly filing a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the SEC) today relating to the proposed public listing of common stock in GAN Limited.
  • The public listing is expected to take place after the SEC completes its review process, subject to market and other conditions.
  • The number of ordinary shares to be offered and the price range for the proposed offering have yet to be determined.
  • The Form F-1 filing includes certain financial information for the year ended December 31, 2019, which is summarized below.

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Tuesday, March 24, 2020 - 2:04pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Monday, March 23, 2020 - 2:03pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.